The Conversation (0)
Cannabis Technologies Inc. (CSE:CAN,OTCQB:CANLF) announced its first therapy, CT1-085. The therapy is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients and will be used for the treatment of Glaucoma.
Cannabis Technologies Inc. (CSE:CAN,OTCQB:CANLF) announced its first therapy, CT1-085. The therapy is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients and will be used for the treatment of Glaucoma.
As quoted in the press release:
Cannabis Technologies Inc. has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma.
Cannabis Technologies CEO, Craig Schneider, said:
The successful discovery & development of CTI-085 demonstrates to the market that our proprietary Cannabinoid Drug Design Platform (CDP) can successfully identify treatments within our proposed target areas. We are looking forward to the continuation of expanding our product pipeline through the utilization of our Platform Technology.
Click here to read the Cannabis Technologies Inc. (CSE:CAN) press release
